GoDaddy (GDDY) reported first-quarter 2025 earnings of $1.27 per share, which missed the Zacks Consensus Estimate by 5.93% but increased 17.6% on a year-over-year basis.GDDY generated revenues of $1.2 billion, surpassing the Zacks Consensus Estimate by 0.6%. Revenues increased 7.7% year over year on a reported and 8% on a constant-currency (cc) basis. Total customers at the end of the first quarter were 20,484, down 2.4% year over year.GDDY’s Quarterly PerformanceApplications and Commerce (A&C), comprising ...

For the quarter ended March 2025, T. Rowe Price (TROW) reported revenue of $1.76 billion, up 0.8% over the same period last year. EPS came in at $2.23, compared to $2.38 in the year-ago quarter.The reported revenue represents a surprise of -0.39% over the Zacks Consensus Estimate of $1.77 billion. With the consensus EPS estimate being $2.09, the EPS surprise was +6.70%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ...

Core Insights - The Cigna Group reported strong first quarter 2025 results, with significant growth across its diversified business portfolio, leading to an increased outlook for full-year earnings [1][2][20] Financial Performance - Shareholders' net income for Q1 2025 was $1.3 billion, or $4.85 per share, compared to a net loss of $0.3 billion, or $0.97 per share, in Q1 2024 [2][7] - Adjusted income from operations for Q1 2025 was $1.8 billion, or $6.74 per share, slightly down from $1.9 billion, or $6.47 per share, in Q1 2024 [3][7] - Total revenues for Q1 2025 increased by 14% to $65.5 billion compared to Q1 2024, driven by growth in existing client relationships and specialty pharmacy services [4][7] Customer Relationships - Total customer relationships as of March 31, 2025, were 182.2 million, reflecting a 1% increase excluding the impact of the HCSC transaction [15] - Total pharmacy customers increased by 3% to 122.3 million, while total medical customers decreased by 6% to 18.0 million, primarily due to the HCSC transaction [15][6] Segment Performance - Evernorth Health Services reported adjusted revenues of $53.7 billion for Q1 2025, with a 16% increase in adjusted income from operations, pre-tax [16] - Cigna Healthcare's adjusted income from operations, pre-tax, was $1.3 billion for Q1 2025, reflecting a slight decrease from the previous year [37] Outlook - The Cigna Group's outlook for full-year 2025 adjusted income from operations is projected to be at least $29.60 per share, an increase of $0.10 from prior projections [20][21]

Labcorp Holdings (LH) reported adjusted earnings per share (EPS) of $3.84 in the first quarter of 2025. The figure rose 4.3% from the year-ago reported level.The adjusted figure excludes the impacts of certain amortization expenses and restructuring charges, among others. The bottom line beat the Zacks Consensus Estimate by 2.9%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)On a GAAP basis, EPS in the first quarter was $2.52 compared with $2.69 in the year-ago period.LH Q1 Revenu ...

Core Insights - Thermo Fisher Scientific Inc. reported first-quarter 2025 adjusted earnings per share (EPS) of $5.15, exceeding the Zacks Consensus Estimate by 1% and reflecting a year-over-year increase of 0.8% [1] - The company's GAAP EPS was $3.98, marking a 15% increase year over year [1] - Following the earnings announcement, shares of Thermo Fisher rose 1.7% in pre-market trading [2] Revenue Performance - Total revenues for the quarter reached $10.36 billion, a 0.2% increase year over year, surpassing the Zacks Consensus Estimate by 1.1% [3] - Organic revenues increased by 1% year over year [3] Segment Analysis - Life Sciences Solutions segment (22.6% of total revenues) saw revenues increase by 2.4% year over year to $2.34 billion, exceeding estimates [4] - Analytical Instruments segment (16.6%) reported a 1.8% year-over-year increase in revenues to $1.72 billion, which fell short of estimates [5] - Specialty Diagnostics segment (11.1%) experienced a 3.5% year-over-year revenue increase to $1.15 billion, surpassing predictions [6] - Laboratory Products and Biopharma Services segment (54.4%) saw a decline of 1.4% year over year, with revenues at $5.64 billion, slightly below estimates [7] Margin Performance - Gross margin for the first quarter was 41.6%, contracting by 5 basis points year over year due to a 0.3% rise in the cost of revenues [8] - Selling, general and administrative expenses decreased by 0.6% to $1.72 billion, while research and development expenses increased by 3.3% to $342 million [8] - Adjusted operating margin was 21.7%, reflecting a contraction of 2 basis points [8] Financial Position - At the end of Q1 2025, cash and cash equivalents and short-term investments totaled $5.95 billion, up from $5.57 billion at the end of Q4 2024 [9] - Net cash from operating activities was $723 million, down from $1.25 billion a year ago [10] - The company has a consistent dividend-paying history, with a five-year annualized dividend growth of 15.10% [10] Strategic Developments - During the first quarter, Thermo Fisher launched several innovative products, including the Thermo Scientific Vulcan Automated Lab and Olink Reveal proteomics kits, contributing to commercial success [12] - The company announced an agreement to acquire Solventum's Purification & Filtration Business for $4.1 billion in cash [12] Overall Assessment - Thermo Fisher's first-quarter results exceeded expectations in terms of earnings and revenues, with growth in most segments except for Laboratory Products and Biopharma Services [11] - The contraction in margins was noted as a concern, and the company is expected to provide guidance for 2025 in an upcoming earnings call [11]